Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05290857

Anticoagulation After GI Bleeding Pilot Study and Registry

Led by Ottawa Hospital Research Institute · Updated on 2025-07-30

100

Participants Needed

2

Research Sites

191 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

PANTHER-GI Pilot Study will assess the feasibility of a full-scale multicentre cohort management study evaluating the safety of a standardized strategy for resuming direct oral anticoagulants (DOACs) after major DOAC-related gastrointestinal (GI) bleeding among patients at moderate to high risk of re-bleeding and thrombosis. A parallel registry will assess whether eligible patients who are not enrolled in the PANTHER-GI Pilot Study are systematically different than enrolled patients and to explore barriers to enrolment.

CONDITIONS

Official Title

Anticoagulation After GI Bleeding Pilot Study and Registry

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female subjects aged 18 years or older
  • Hospitalized with acute major non-variceal GI bleeding while receiving oral anticoagulant therapy
  • Oral anticoagulant therapy discontinued for current acute GI bleed and not yet resumed
  • Ongoing indication for long-term anticoagulation of atrial fibrillation with CHA2DS2VASc score 3 or higher or venous thromboembolism
  • Planned to resume direct oral anticoagulants after bleeding
  • At moderate to high risk of re-bleeding as assessed by clinical team
  • Clinical hemostasis achieved as assessed by clinical team
  • Able and willing to comply with follow-up examinations in the consent form
Not Eligible

You will not qualify if you...

  • Mechanical heart valve
  • Venous thromboembolism related to a major transient risk factor with completed 3 months treatment
  • Gastrointestinal bleeding managed surgically (e.g., gastrectomy, colectomy)
  • Active or previously treated gastrointestinal cancer
  • Life expectancy less than 3 months from other causes
  • Platelet count below 50,000/µL
  • Renal dysfunction with creatinine clearance below 30 mL/min

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Alberta Health Services - Peter Lougheed Center Endoscopy Unit

Calgary, Alberta, Canada, T1Y 6J4

Actively Recruiting

2

Ottawa Hospital Research Institute

Ottawa, Ontario, Canada, K1H8L6

Actively Recruiting

Loading map...

Research Team

D

Deborah M Siegal, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here